Skip to content
Disclosery

SR One Capital Management, LP

Follow

13F filer, CIK 1910264, Redwood City, CA

SR One Capital Management, LP reported $461,375,729 across 13 holdings for the quarter ended 2025-06-30, in a 13F-HR filed 2025-08-14. Its ten largest share positions make up 97.75% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0000950123-25-008422

Period
2025-06-30
Reported value
$461M
Holdings
13
Top 10 weight
97.75%
New
1
Sold out
0

Largest buys vs the previous quarter

SecurityShares changeApprox. value
ORICnew+4,514,929$45.8M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

None.

Holdings, Q2 2025

Share positions as resolved from 13F-HR 0000950123-25-008422, largest first. % of portfolio is the value over $461,375,729, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
ACLXARCELLX INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 2,346,630 shares; 2024Q4: 2,346,630 shares; 2025Q1: 2,346,630 shares; 2025Q2: 2,346,630 shares 2,346,630$155M33.49%0Timeline
SPRYARS PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 4,012,903 shares; 2024Q4: 4,012,903 shares; 2025Q1: 4,012,903 shares; 2025Q2: 4,012,903 shares 4,012,903$70M15.18%0Timeline
CRSPCRISPR THERAPEUTICS AGQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,048,951 shares; 2024Q4: 1,048,951 shares; 2025Q1: 1,048,951 shares; 2025Q2: 1,048,951 shares 1,048,951$51M11.06%0Timeline
ZBIOZENAS BIOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 4,911,539 shares; 2024Q4: 4,911,539 shares; 2025Q1: 4,911,539 shares; 2025Q2: 4,911,539 shares 4,911,539$47.6M10.32%0Timeline
ORICORIC PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 4,514,929 shares 4,514,929$45.8M9.93%newTimeline
MLYSMINERALYS THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 2,016,822 shares; 2024Q4: 2,016,822 shares; 2025Q1: 3,127,933 shares; 2025Q2: 3,127,933 shares 3,127,933$42.3M9.17%0Timeline
DSGNDESIGN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 6,526,476 shares; 2024Q4: 6,526,476 shares; 2025Q1: 6,526,476 shares; 2025Q2: 6,526,476 shares 6,526,476$22M4.77%0Timeline
OCSOCULIS HOLDING AGQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 322,500 shares; 2025Q2: 322,500 shares 322,500$6.26M1.36%0Timeline
ALMSALUMIS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,959,896 shares; 2024Q4: 1,959,896 shares; 2025Q1: 1,959,896 shares; 2025Q2: 1,959,896 shares 1,959,896$5.88M1.27%0Timeline
NKTXNKARTA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 3,333,333 shares; 2024Q4: 3,333,333 shares; 2025Q1: 3,333,333 shares; 2025Q2: 3,333,333 shares 3,333,333$5.53M1.2%0Timeline
ORKAORUKA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 375,330 shares; 2024Q4: 430,330 shares; 2025Q1: 430,330 shares; 2025Q2: 430,330 shares 430,330$4.82M1.05%0Timeline
KALAKALA BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 443,661 shares; 2024Q4: 598,940 shares; 2025Q1: 598,940 shares; 2025Q2: 598,940 shares 598,940$2.85M0.62%0Timeline
ENGNENGENE HOLDINGS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 747,750 shares; 2024Q4: 747,750 shares; 2025Q1: 747,750 shares; 2025Q2: 747,750 shares 747,750$2.72M0.59%0Timeline

How Q2 2025 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0000950123-25-008422 base2025-08-14acceptance time not in the bulk data set